DOPAGON TABLET-Egypt

Composition:

Each tablet contains:
Bromocriptine mesylate                   2.87mg
(eq. to Bromocriptine 2.5 mg) 

Pharmacological properties:
Bromocriptine mesylate is a dopamine receptor agonist which activates post-synaptic dopamine receptors.The dopaminergic neurons modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin  inhibitory factor. Bromocriptine mesylate is a nonhormonal, nonestrogenic agent that inhibits the secretion of prolactin in human. In about 75% of cases of amenorrhea and galactorrhea, Bromocriptine mesylate therapy suppresses the galactorrhea or almost completely and reinitiates normal ovulatory menstrual cycles. In many acromegalic patients, Bromocriptine, mesylate produces a prompt and sustained reduction in circulating levels of serum growth hormone. 

Pharmacokinetics:
Bromocriptine is absorbed from G I T, Completely metabolized.The major route of excretion is the bile. Almost all (84.6%) of the administered dose is excreted in the feces in 120 hours.                     

Indications:

- Hyperprolactinemia-associated dysfunctions; including amenorrhea with or without galactorrhea, infertility or hypogonadism, prolactin secreting adenomas.
- Acromegaly - Parkinson's disease as adjunct to L-dopa.